Skip to content
10-Q

Quarterly Report

AKARI THERAPEUTICS, PLC AKTX

0001493152-26-024446

← back to feed
Filed
May 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 19, 2026 91.57B sh
Shares Diluted Q1 2026 · Mar 31, 2026 118.76B sh
Shares Diluted Q1 2026 · Mar 31, 2025 54.59B sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.49M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.15M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.77M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $5.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $14.38M
Stockholders Equity Q1 2026 · Dec 31, 2025 $28.33M
Stockholders Equity Q1 2026 · Mar 31, 2025 $21.75M
Stockholders Equity Q1 2026 · Dec 31, 2024 $22.23M
Current Liabilities Q1 2026 · Mar 31, 2026 $13.42M
Current Liabilities Q1 2026 · Dec 31, 2025 $12.35M
Total Liabilities Q1 2026 · Mar 31, 2026 $19.51M
Total Liabilities Q1 2026 · Dec 31, 2025 $19.56M
Current Assets Q1 2026 · Mar 31, 2026 $3.59M
Current Assets Q1 2026 · Dec 31, 2025 $5.46M
Total Assets Q1 2026 · Mar 31, 2026 $33.89M
Total Assets Q1 2026 · Dec 31, 2025 $47.89M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $2.17M
Sga Expense Q1 2026 · Mar 31, 2025 $2.71M
Rd Expense Q1 2026 · Mar 31, 2026 $1.46M
Rd Expense Q1 2026 · Mar 31, 2025 $813K
Net Income Q1 2026 · Mar 31, 2026 −$14.46M
Net Income Q1 2026 · Mar 31, 2025 −$3.71M
Operating Income Q1 2026 · Mar 31, 2026 −$15.76M
Operating Income Q1 2026 · Mar 31, 2025 −$3.53M